News

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
Detailed price information for Cardiff Oncology Inc (CRDF-Q) from The Globe and Mail including charting and trades.
The American Journal of Managed Care2h
Addressing Unmet Needs in Lung Cancer to Optimize Precision Medicine and Immunotherapy: Angel Qin, MD
Angel Qin, MD, identified the critical role of immunotherapy timing and shared decision-making in small cell lung cancer ...
Zacks Investment Research on MSN4h
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology PBYI reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus ...
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum ...